| 000 | 00866 a2200217 4500 | ||
|---|---|---|---|
| 005 | 20250517143338.0 | ||
| 008 | ####s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/01.wnl.0000496643.57775.41 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCahir-McFarland, Ellen | |
| 245 | 0 | 0 |
_aCD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response. _h[electronic resource] |
| 260 |
_bNeurology _c08 2016 |
||
| 300 |
_a958-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 700 | 1 | _aRansohoff, Richard M | |
| 700 | 1 | _aLieberman, Linda | |
| 700 | 1 | _aPlavina, Tatiana | |
| 773 | 0 |
_tNeurology _gvol. 87 _gno. 9 _gp. 958-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/01.wnl.0000496643.57775.41 _zAvailable from publisher's website |
| 999 |
_c26971167 _d26971167 |
||